Recent presales momentum for the R-rated DC body-horror origin story has stalled ahead of its October 23 wide release, pushing most industry tracking into the $18–25 million range despite earlier $25–30 million forecasts. Modest awareness levels, competition from the expanding A24 documentary “You Can See Everything” that posted the biggest nonfiction debut in over two decades, and a post-Supergirl caution around DC properties have tempered trader expectations. Mixed-to-positive early reviews (74 percent on Rotten Tomatoes) and a low-to-mid $30 million budget provide some cushion, but the market-implied odds reflect the tight contest between sub-$22 million and $22–25 million outcomes driven by last-minute ticket data and word-of-mouth potential.